Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine

D M Ficker; M Privitera; G Krauss; A Kanner; J L Moore; T Glauser

doi:10.1212/01.wnl.0000172932.95985.51

Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine

Neurology. 2005 Aug 23;65(4):593-5. doi: 10.1212/01.wnl.0000172932.95985.51.

Authors

D M Ficker¹, M Privitera, G Krauss, A Kanner, J L Moore, T Glauser

Affiliation

¹ Department of Neurology, University of Cincinnati Medical Center, 231 Albert B. Sabin Way, Cincinnati, OH 45267, USA. david.ficker@uc.edu

PMID: 16116122
DOI: 10.1212/01.wnl.0000172932.95985.51

Abstract

The authors conducted a 3-month, prospective, open-label study assessing the effects of switching from immediate-release carbamazepine formulations to an equal total daily dose of carbamazepine extended-release capsules (CBZ-ERC) in adolescents and adults with epilepsy. Using validated, epilepsy-specific measures the authors found that switching to CBZ-ERC significantly improved patients' adverse events and quality-of-life measures. Switching to CBZ-ERC also improved seizure control.

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Anticonvulsants / administration & dosage*
Anticonvulsants / adverse effects
Carbamazepine / administration & dosage*
Carbamazepine / adverse effects
Child, Preschool
Confusion / chemically induced
Consciousness Disorders / chemically induced
Dose-Response Relationship, Drug
Drug Administration Schedule
Epilepsy / drug therapy*
Female
Humans
Male
Prospective Studies
Secondary Prevention
Treatment Outcome

Substances

Anticonvulsants
Carbamazepine